Showing 1 - 10 of 11
Persistent link: https://www.econbiz.de/10012612587
We analyze some of the perverse incentives that may arise under the current Medicare prescription drug benefit design. In particular, risk adjustment for a stand-alone prescription drug benefit creates perverse incentives for prescription drug plans' coverage decisions and/or pharmaceutical...
Persistent link: https://www.econbiz.de/10013231611
Persistent link: https://www.econbiz.de/10003287666
Persistent link: https://www.econbiz.de/10003573628
Persistent link: https://www.econbiz.de/10001591809
Persistent link: https://www.econbiz.de/10003013599
Crestor, an important but controversial cholesterol-lowering drug, is contraindicated for use by senior and Asian patients. In this paper, we exploit this fact and a unique doctor-level prescription and advertising (detailing, to be exact) exposure data for statin drugs to examine the hypothesis...
Persistent link: https://www.econbiz.de/10012940309
Persistent link: https://www.econbiz.de/10012098703
Exploiting a rich panel data set on anti-ulcer drug prescriptions, we measure the effects of uncertainty and learning in the demand for pharmaceutical drugs. We estimate a dynamic matching model of demand under uncertainty in which patients learn from prescription experience about the...
Persistent link: https://www.econbiz.de/10012783639
We analyze some of the perverse incentives that may arise under the current Medicare prescription drug benefit design. In particular, risk adjustment for a stand-alone prescription drug benefit creates perverse incentives for prescription drug plans' coverage decisions and/or pharmaceutical...
Persistent link: https://www.econbiz.de/10012466663